Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Resistance to antiretroviral therapy among patients in Uganda
Autore:
Weidle, PJ; Kityo, CM; Mugyenyi, P; Downing, R; Kebba, A; Pieniazek, D; Respess, R; Hertogs, K; De Vroey, V; Dehertogh, P; Bloor, S; Larder, B; Lackritz, E;
Indirizzi:
CDCP, Div HIV AIDS Prevent, Natl Ctr HIV Transmitted Dis & TB Prevent, Atlanta, GA 30333 USA CDCP Atlanta GA USA 30333 smitted Dis & TB Prevent, Atlanta, GA 30333 USA Joint Clin Res Ctr, Kampala, Uganda Joint Clin Res Ctr Kampala UgandaJoint Clin Res Ctr, Kampala, Uganda Uganda Virus Res Inst, Entebbe, Uganda Uganda Virus Res Inst Entebbe Uganda da Virus Res Inst, Entebbe, Uganda VIRCO NV, Mechelen, Belgium VIRCO NV Mechelen BelgiumVIRCO NV, Mechelen, Belgium CDC, Div AIDS STD, TB Lab Res, Natl Ctr Infect Dis, Atlanta, GA 30333 USA CDC Atlanta GA USA 30333 Res, Natl Ctr Infect Dis, Atlanta, GA 30333 USA VIRCO Ltd, Cambridge, England VIRCO Ltd Cambridge EnglandVIRCO Ltd, Cambridge, England
Titolo Testata:
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
fascicolo: 5, volume: 26, anno: 2001,
pagine: 495 - 500
SICI:
1525-4135(20010415)26:5<495:RTATAP>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; DRUG SUSCEPTIBILITY; SUBTYPE-B; PROTEASE INHIBITORS; SEQUENCE; HIV; SEROCONVERTERS; INDIVIDUALS; DIVERSITY;
Keywords:
Africa-antiretroviral therapy; epidemiology; HIV drug resistance/resistance mutations; HIV subtypes; AF358736; AF358760;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Weidle, PJ CDCP, Div HIV AIDS Prevent, Natl Ctr HIV Transmitted Dis & TB Prevent, Mailstop E-45,1600 Clifton Rd, Atlanta, GA 30333 USA CDCP Mailstop E-45,1600 Clifton Rd Atlanta GA USA 30333 333 USA
Citazione:
P.J. Weidle et al., "Resistance to antiretroviral therapy among patients in Uganda", J ACQ IMM D, 26(5), 2001, pp. 495-500

Abstract

Objective: To characterize HIV-1 phenotypic resistance patterns and genotypic mutations among patients taking antiretroviral medications in Uganda. Methods: We reviewed charts and retrieved archived plasma specimens from patients at an AIDS specialty center in Uganda where antiretroviral therapy has been used since 1996. Phenotypic and genotypic resistance testing was done on specimens associated with a viral load of 1000 copies/ml. Results: Resistance testing of specimens was completed for 16 patients. Among 11 specimens collected before initiation of antiretroviral therapy, no phenotypic resistance or primary genotypic mutations were found. Among 8 patients taking lamivudine, phenotypic resistance was found for 9 (90%) of 10specimens and was associated with an M184V mutation in all nine cases. Among 12 patients taking zidovudine, no phenotypic resistance and few primary mutations were found. For 6 patients who were receiving protease inhibitors, we observed no phenotypic resistance and only one primary genotypic mutation associated with resistance. Conclusions: The absence of apparent resistance among samples collected before antiretroviral therapy supports the notion that a similar approach to selection of antiretroviral therapy can generally be used against non-B subtypes. A genotypic marker of antiretroviral resistance to lamivudine in HIV-1 subtypes A, C, and D was similar to those in subtype B infections. Theseresults suggest that the methods used for monitoring for the emergence of drug resistance in antiretroviral programs in Africa may be similar to those used in developed settings.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 23:52:08